Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 104 publications
Speeding to a Stop: Postapproval Barriers to Accessing New Lung Cancer Therapies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2026
Utility of artificial intelligence for identifying thoracic lymphadenopathy in lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 18, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: March 30, 2026
Weight Gain on Lorlatinib Is Associated With Accumulation of Visceral Adipose Tissue.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 10, 2026
Weight Gain on Lorlatinib is Associated with Accumulation of Visceral Adipose Tissue.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 10, 2026
Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer.
Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 09, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 19, 2025
Reply to the Letter to the Editor From Lee et al.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: September 16, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
Journal: Nature medicine
Published: September 04, 2025
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.
Journal: JCO oncology practice
Published: March 07, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Journal: The Lancet. Oncology
Published: February 28, 2025
Last Updated: 09/26/2026